Efficacy of metformin in the treatment of metabolic syndrome in patients with schizophrenia and its relationship with chronic inflammatory state
LI Meihua1, ZHU Cheng1, ZHENG Ke2, LIU Jiahong1, LYU Wei1.
1.Department of General Psychiatry, Kangning Hospital Affiliated to Wenzhou Medical University,Wenzhou 325000, China; 2.Department of Behavioral Medicine, Kangning Hospital Affiliated to Wenzhou Medical University, Wenzhou 325000, China
LI Meihua,ZHU Cheng,ZHENG Ke, et al. Efficacy of metformin in the treatment of metabolic syndrome in patients with schizophrenia and its relationship with chronic inflammatory state[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2022, 52(5): 382-387.
Abstract：Objective: To analyze the efficacy of metformin in the treatment of metabolic syndrome in patients with schizophrenia, and to further analyze the effect of the C-reactive protein (CRP) changes and tumor necrotic factor-α (TNF-α) on metabolic syndrome. Methods: According to the medical record number, 100 patients with schizophrenia who met the inclusion criteria and exclusion criteria were randomly divided into study group (n=50) and control group (n=50). Body mass index (BMI), homeostasis insulin evaluation index (HOMA-IR), fasting plasma glucose (FPG), glycosylated hemoglobin (HbA1c), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C), total cholesterol (TC), triglyceride (TG), CRP,TNF-α were measured before and 24 weeks after intervention treatment. Collected data were analyzed by SPSS.Results: There was no significant difference in sex, education, marriage, family history, course of disease, age and dose distribution of olanzapine between the study group and the control group (P>0.05). ΔBMI, ΔHOMA-IR,ΔFPG, ΔHbA1c, ΔHDL-C, ΔLDL-C, ΔTC, ΔTG, ΔCRP, ΔTNF-α in the study group was significantly higher than those in the control group after intervention (P<0.05). ΔCRP and ΔTNF-α in the study group had significantly positive correlation with ΔBMI and ΔHOMA-IR. ΔCRP could explain 13.4% of the ΔBMI variation and 11.4% of the ΔHOMA-IR variation, while 12.5% of the ΔBMI variation and 14.2% of the ΔHOMA-IR variation could be respectively explained by ΔTNF-α. Conclusion: Metformin can effectively improve the metabolic syndrome in patients with schizophrenia, while the improvement of metabolic syndrome may be related to the reduction of inflammatory state.
